LiveWire YouTube Link, page-74

@redram

I agree that their price estimates are not backed by substantial research (it's just not possible for the number of companies they cover).

My comment was my own opinion - that on a traditional valuation perspective PET runs high. Even if they meet the 31 Dec forecast an investor will still be valuing every dollar of the companies sales with $30 of their own. And of course the price to earnings ratio will be multiples higher again.

These valuation techniques are of course just part of the picture but they are commonplace and it's how some firms (such as Morningstar) derive their assessments. They are also useful for retail investors looking to compare companies in a field of choice.

It's helpful that PET has other advantages going for it, which have already been covered here (no debt, large TAM, established relationships with China, proven success of product, strong historical growth etc.).